Abstract

Synaptic loss is one of the major features of Alzheimer's disease (AD) and correlates with the degree of dementia. N-methyl-d-aspartate receptors (NMDARs) have been shown to mediate downstream effects of the β-amyloid peptide (Aβ) in AD models. NMDARs can trigger intracellular cascades via Ca2+ entry, however, also Ca2+-independent (metabotropic) functions of NMDARs have been described. We aimed to determine whether ionotropic or metabotropic NMDAR signaling is required for the induction of synaptic loss by Aβ. We show that endogenous Aβ as well as exogenously added synthetic Aβ oligomers induced dendritic spine loss and reductions in pre- and postsynaptic protein levels in hippocampal slice cultures. Synaptic alterations were mitigated by blocking glutamate binding to NMDARs using NMDAR antagonist APV, but not by preventing ion flux with Ca2+ chelator BAPTA or open-channel blockers MK-801 or memantine. Aβ increased the activity of p38 MAPK, a kinase involved in long-term depression and inhibition of p38 MAPK abolished the loss of dendritic spines. Aβ-induced increase of p38 MAPK activity was prevented by APV but not by BAPTA, MK-801 or memantine treatment highlighting the role of glutamate binding to NMDARs but not Ca2+ flux for synaptic degeneration by Aβ. We further show that treatment with the G protein inhibitor pertussis toxin (PTX) did not prevent dendritic spine loss in the presence of Aβ oligomers. Our data suggest that Aβ induces the activation of p38 MAPK and subsequent synaptic loss through Ca2+ flux- and G protein-independent mechanisms.

Highlights

  • Alzheimer’s disease (AD) is clinically characterized by cognitive impairments caused by massive neuronal degeneration and synaptic loss

  • We show that the β-amyloid peptide (Aβ)-induced pre- and postsynaptic loss is mediated by glutamate binding to N-methyl-D-aspartate receptor (NMDAR), independent of ion influx

  • Our data show that NMDAR-dependent ion flux is not required for synaptic loss, whereas binding of glutamate to the NMDAR is essential for coupling Aβ with synaptic degeneration

Read more

Summary

Introduction

Alzheimer’s disease (AD) is clinically characterized by cognitive impairments caused by massive neuronal degeneration and synaptic loss. The levels of soluble oligomeric forms of β-amyloid peptide (Aβ) but not plaques correlates best with memory loss in AD.[2] Accumulating evidence indicates that transgenically produced Aβ or the treatment with Aβ oligomers decrease dendritic spine density,[3,4,5,6] impair long-term potentiation (LTP),[7] facilitate long-term depression (LTD)[8] and induce aberrant spine morphology.[5,9]. Upon glutamate binding to the NR2 subunit of NMDARs, cations including Ca2+ enter the cell. It has been thought for a long time that the levels of Ca2+ influx through NMDARs determine the induction of either LTP

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.